WO2009001555A1 - Régulateur de l'expression d'interféron de type i - Google Patents

Régulateur de l'expression d'interféron de type i Download PDF

Info

Publication number
WO2009001555A1
WO2009001555A1 PCT/JP2008/001648 JP2008001648W WO2009001555A1 WO 2009001555 A1 WO2009001555 A1 WO 2009001555A1 JP 2008001648 W JP2008001648 W JP 2008001648W WO 2009001555 A1 WO2009001555 A1 WO 2009001555A1
Authority
WO
WIPO (PCT)
Prior art keywords
interferon
type
expression
controller
protein
Prior art date
Application number
PCT/JP2008/001648
Other languages
English (en)
Japanese (ja)
Inventor
Tsukasa Seya
Misako Matsumoto
Hiroyuki Oshiumi
Original Assignee
National University Corporation Hokkaido University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National University Corporation Hokkaido University filed Critical National University Corporation Hokkaido University
Priority to JP2009520351A priority Critical patent/JPWO2009001555A1/ja
Publication of WO2009001555A1 publication Critical patent/WO2009001555A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne un régulateur d'expression grâce auquel l'induction de l'expression d'interféron de type I peut être régulée. Un régulateur de l'expression d'interféron de type I est une protéine comportant la séquence d'acides aminés représentée par SEQ ID NO:1 ; et/ou une protéine comportant une séquence d'acides aminés dérivant de la séquence d'acides aminés représentée par SEQ ID NO:1 par délétion, substitution ou addition d'un ou de plusieurs acides aminés. Son activité consiste à favoriser ou à inhiber la transcription d'un interféron de type I par un promoteur en présence d'une protéine RIG-I. Par conséquent, un régulateur d'expression grâce auquel la production d'IFN-I peut être favorisée ou inhibée peut être proposé. Ce régulateur peut être utilisé pour traiter une maladie infectieuse ou une inflammation.
PCT/JP2008/001648 2007-06-26 2008-06-25 Régulateur de l'expression d'interféron de type i WO2009001555A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2009520351A JPWO2009001555A1 (ja) 2007-06-26 2008-06-25 Ｉ型インターフェロンの発現調節剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-168187 2007-06-26
JP2007168187 2007-06-26

Publications (1)

Publication Number Publication Date
WO2009001555A1 true WO2009001555A1 (fr) 2008-12-31

Family

ID=40185380

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/001648 WO2009001555A1 (fr) 2007-06-26 2008-06-25 Régulateur de l'expression d'interféron de type i

Country Status (2)

Country Link
JP (1) JPWO2009001555A1 (fr)
WO (1) WO2009001555A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003025142A2 (fr) * 2001-09-16 2003-03-27 Nuvelo, Inc. Nouveaux acides nucleiques et polypeptides secretes
US20050272061A1 (en) * 2004-02-19 2005-12-08 Seattle Genetics, Inc. Expression profiling in non-small cell lung cancer
JP2007054042A (ja) * 2005-07-26 2007-03-08 Japan Science & Technology Agency インターフェロン誘導分子ｉｐｓ−１

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003025142A2 (fr) * 2001-09-16 2003-03-27 Nuvelo, Inc. Nouveaux acides nucleiques et polypeptides secretes
US20050272061A1 (en) * 2004-02-19 2005-12-08 Seattle Genetics, Inc. Expression profiling in non-small cell lung cancer
JP2007054042A (ja) * 2005-07-26 2007-03-08 Japan Science & Technology Agency インターフェロン誘導分子ｉｐｓ−１

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ARIMOTO K. ET AL.: "Negative regulation of the RIG-I signaling by the ubiquitin ligase RNF125", PROC. NATL. ACAD. SCI. USA, vol. 104, no. 18, 1 May 2007 (2007-05-01), pages 7500 - 7505 *
ARIMOTO K. ET AL.: "Ubiquitin-ka ni yoru Ko Virus Oto no Chosetsu", IGAKU NO AYUMI, vol. 224, no. 2, 12 January 2008 (2008-01-12), pages 171 - 172 *
DATABASE GENBANK [online] 23 October 2006 (2006-10-23), "Homo sapiens ring finger protein 135, mRNA", Database accession no. (BC126422) *
DOUGLAS J. ET AL.: "mutations in RNF135, a gene within the NF1 microdeletion region, cause phenotypic abnormalities including overgrowth", NAT. GENET., vol. 39, no. 8, August 2007 (2007-08-01), pages 963 - 965 *
GACK M.U. ET AL.: "TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity", NATURE, vol. 446, no. 7138, April 2007 (2007-04-01), pages 916 - 920 *
HEMMI H. ET AL.: "The roles of two IkappaB kinase-related kinases in lipopolysaccharide and double stranded RNA signaling and viral infection", J. EXP. MED., vol. 199, no. 12, 2004, pages 1641 - 1650 *
JOAZEIRO C.A. ET AL.: "RING finger proteins: mediators of ubiquitin ligase activity", CELL, vol. 102, no. 5, 2000, pages 549 - 552, XP002230254 *
LIN R. ET AL.: "Negative regulation of the retinoic acid-inducible gene I-induced antiviral state by the ubiquitin-editing protein A20", J. BIOL. CHEM., vol. 281, no. 4, 2006, pages 2095 - 2103 *
YONEYAMA M. ET AL.: "The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses", NAT. IMMUNOL., vol. 5, no. 7, July 2004 (2004-07-01), pages 730 - 737, XP003017392 *

Also Published As

Publication number Publication date
JPWO2009001555A1 (ja) 2010-08-26

Similar Documents

Publication Publication Date Title
NZ600690A (en) Fkbp-l and uses thereof
IN2012DN01652A (fr)
EP2455459A3 (fr) Variantes de lipase pour utilisation pharmaceutique
NZ628756A (en) Immunogens for hiv vaccination
NZ602845A (en) Inhibiting peptides derived from trem-like transcript 1 (tlt-1) and uses thereof
NZ596764A (en) N-glycan core beta-galactosyltransferase and uses thereof
MX2008009493A (es) Peptido novedoso y uso del mismo.
WO2007089851A3 (fr) Compositions et procedes de traitement des maladies mediees par le collagene
NZ600189A (en) Novel 7beta-hydroxysteroid dehydrogenases and their use
NZ598351A (en) Il-17 binding compounds and medical uses thereof
EA201170878A1 (ru) Полипептиды с ксиланазной активностью
WO2014202622A3 (fr) Gène de rasamsonia et son utilisation
NZ586430A (en) Mutant forms of streptolysin o (slo)
MX365095B (es) Métodos y composiciones para incrementar la producción de ácido siálico y tratar condiciones de enfermedades relacionadas siálicas.
ATE326523T1 (de) Verfahren zur fermentativen herstellung von l- methionin
WO2014036806A8 (fr) Gène de tolérance au glyphosate et utilisation de celui-ci
WO2010057242A3 (fr) Vaccin
NZ595231A (en) Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use
IN2014KN00866A (fr)
WO2008058951A8 (fr) Procédé de réduction enzymatique de dérivés d'alcène
NZ590011A (en) Chloramphenicol acetyl transferase (cat)-defective somatostatin fusion protein and uses thereof
TW200806302A (en) Short interference ribonucleic acids for treating allergic dieases
WO2010026219A3 (fr) Nouveaux facteurs de réponse à l’éthylène de la tomate et leurs utilisations
WO2011037349A3 (fr) Système de délivrance de médicament spécifique de la cible, système de délivrance de médicament à action durable non spécifique de la cible et procédé de régulation de la spécificité de cible dudit système
WO2009148229A3 (fr) Peptide immunogène et composition contenant le peptide destinée à prévenir ou à traiter des maladies liées au vph

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08790089

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009520351

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08790089

Country of ref document: EP

Kind code of ref document: A1